Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Classic Gathering Of shares

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Mar 18, 2021 11:26am

192 Views

Post# 32825883

RE:RE:RE:Classic Gathering Of shares

Yeah seeing a couple bumps in share buys at ~40k shares and ~16k shares earlier. We'll see if those continue to roll in today but I'm expecting to see the price fluctuate a bit around those. How many more we see that knock off those loose shares will be interesting!

<< Previous

Bullboard Posts

Next >>

They started in video game investing, now they serve high net worth traders